FLT3 Ligand, CD40 Agonist Antibody, and Stereotactic Radiotherapy

NCT04491084 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

5

Enrollment

OTHER

Sponsor class

Stopped Low accrual

Conditions

Non Small Cell Lung Cancer
Lung Cancer

Interventions

DRUG: FLT3 Ligand (CDX-301)
BIOLOGICAL: anti-CD40 antibody (CDX-1140)
RADIATION: SBRT

Sponsor

Albert Einstein College of Medicine

Collaborators

[object Object]